QL2108
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 19, 2025
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
(clinicaltrials.gov)
- P3 | N=520 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1